Regulus Therapeutics
RGLS
$2.27
Share price
2.25%
Change (1 day)
66.91%
Change (1 year)
Categories
Regulus Therapeutics (RGLS) - Net assets
Net assets on the balance sheet as of September 2023 : $28.25 M
According to Regulus Therapeutics's latest financial reports the company has $28.25 M in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Regulus Therapeutics - Net assets on balance sheet (from 2011 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $33.29 M | -39.42% |
| 2021-12-31 | $54.95 M | 111.17% |
| 2020-12-31 | $26.02 M | 30.03% |
| 2019-12-31 | $20.01 M | -441.9% |
| 2018-12-31 | $-5.86 M | -116.62% |
| 2017-12-31 | $35.21 M | -37.2% |
| 2016-12-31 | $56.07 M | -54.81% |
| 2015-12-31 | $0.12 B | -6.01% |
| 2014-12-31 | $0.13 B | 41.26% |
| 2013-12-31 | $93.45 M | 50.51% |
| 2012-12-31 | $62.09 M | -249.64% |
| 2011-12-31 | $-41.5 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $82.20 B | 290,792.81% | 🇫🇷 France |
 Biogen BIIB | $14.79 B | 52,270.57% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $29.48 B | 104,238.44% | 🇺🇸 USA |
 AstraZeneca AZN | $39.16 B | 138,496.55% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $16.28 B | 57,538.27% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | $82.88 M | 193.31% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -$0.23 B | -880.79% | 🇺🇸 USA |